BMY Bristol Myers Squibb

Q3 2025 10-Q

Filed: Oct 30, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Bristol Myers Squibb (BMY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue details not explicitly provided in excerpt; focus on expense trends instead
• Operating expenses $9.11B Q3 2025 vs $10.22B Q3 2024, down 11% YoY; YTD $27.83B vs $44.51B, down 37% YoY

+7 more insights

Risk Factors

• No newly added risk factors explicitly stated this quarter, focus on product approvals updates
• Regulatory risk from accelerated approvals of Opdivo + Yervoy for multiple indications in Japan, EC, and FDA between Feb-Aug 2025

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$12.2B

▲ +2.8% YoY▼ -0.4% QoQ

Net Income

$2.2B

▲ +81.8% YoY▲ +68.0% QoQ

Net Margin

18.0%

▲ +783bp YoY▲ +733bp QoQ

Source: XBRL data from Bristol Myers Squibb Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Bristol Myers Squibb Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Bristol Myers Squibb

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.